

Georg C. Terstappen

AbbVie Deutschland GmbH & Co. KG
Knollstrasse
67061 Ludwigshafen
Tel.: +49 (0)621-589-3245
Fax: +49 (0)621-589-3232
E-Mail: georg.terstappen@abbvie.com
www.abbvie.com

Georg C. Terstappen is the Director of the Biology Department in Neuroscience Discovery at AbbVie in Ludwigshafen, Germany. He is also the global leader of AbbVie's Blood-Brain-Barrier Initiative and a PI in several IMI projects in the context of brain delivery of macromolecules and human induced pluripotent stem cells. In addition, he is also an adjunct Professor of Biotechnology at the University of Applied Sciences in Mannheim (Germany).

Prior to joining AbbVie in January 2011, he was the Chief Scientific Officer of Siena Biotech, a drug discovery company he co-initiated in 2002. From 2005-2010 he was also the coordinator of ADIT, a European-wide collaborative research project in target and lead discovery for Alzheimer's disease funded by the EC's FP6. In this period he was also co-proponent and PI of two Marie Curie academic-industrial networks in the context of polyglutamine diseases including Huntington's and Parkinson's disease (NEUROMODEL and TreatPolyQ) funded by the EC's FP7.

Georg has more than 20 years of experience in CNS drug discovery, is an inventor/co-inventor of 14 patents and an author of more than 70 scientific publications. He previously worked at Bayer AG, GlaxoWellcome and GlaxoSmithKline where his last position was Director of Systems Research. Prior to joining the pharmaceutical industry in 1992, he conducted research at the Max-Planck-Institute in Cologne and the Federal Research Centre Juelich (Germany) for which he received his PhD in biochemistry.

CNS drug discovery
Neurodegenerative diseases (AD, MS, PD, HD)
Target discovery
Lead discovery
Application of human induced pluripotent stem cells for CNS drug discovery
Innovative brain delivery technologies for macromolecular drug molecules
Biochemical biomarkers